UK's Syn­thace rais­es $35M in Se­ries C; On­col­o­gy and in­flam­ma­to­ry dis­ease biotech De­ka hauls in $20M Se­ries A

UK-based AI-as­sist­ed R&D biotech Syn­thace just wrapped up a Se­ries C round, bring­ing in $35 mil­lion.

Per a com­pa­ny state­ment this morn­ing, the in­vest­ment will fu­el com­mer­cial and go-to-mar­ket (GTM) growth as Syn­thace con­tin­ues to ex­pand across the At­lantic in­to the US. This in­cludes plans to ex­pand its lead­er­ship team by bring­ing in new VPs of mar­ket­ing and sales to join US-based Guy Levy-Yurista, Syn­thace’s CEO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER